Logo image of ALHYP.PA

HIPAY GROUP SA (ALHYP.PA) Stock Fundamental Analysis

Europe - EPA:ALHYP - FR0012821916 - Common Stock

9 EUR
-0.4 (-4.26%)
Last: 10/31/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, ALHYP scores 3 out of 10 in our fundamental rating. ALHYP was compared to 50 industry peers in the Financial Services industry. ALHYP may be in some trouble as it scores bad on both profitability and health. ALHYP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

ALHYP had positive earnings in the past year.
The reported net income has been mixed in the past 5 years: ALHYP reported negative net income in multiple years.
Of the past 5 years ALHYP 4 years had a positive operating cash flow.
ALHYP.PA Yearly Net Income VS EBIT VS OCF VS FCFALHYP.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

With a Return On Assets value of 0.55%, ALHYP perfoms like the industry average, outperforming 42.00% of the companies in the same industry.
ALHYP has a Return On Equity of 3.09%. This is comparable to the rest of the industry: ALHYP outperforms 52.00% of its industry peers.
ALHYP has a Return On Invested Capital of 6.43%. This is in the better half of the industry: ALHYP outperforms 70.00% of its industry peers.
Industry RankSector Rank
ROA 0.55%
ROE 3.09%
ROIC 6.43%
ROA(3y)-0.13%
ROA(5y)-0.88%
ROE(3y)-2.18%
ROE(5y)-5.3%
ROIC(3y)N/A
ROIC(5y)N/A
ALHYP.PA Yearly ROA, ROE, ROICALHYP.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

Looking at the Profit Margin, with a value of 1.54%, ALHYP is doing worse than 60.00% of the companies in the same industry.
ALHYP has a Operating Margin of 6.24%. This is in the lower half of the industry: ALHYP underperforms 60.00% of its industry peers.
ALHYP has a Gross Margin of 52.12%. This is comparable to the rest of the industry: ALHYP outperforms 56.00% of its industry peers.
In the last couple of years the Gross Margin of ALHYP has grown nicely.
Industry RankSector Rank
OM 6.24%
PM (TTM) 1.54%
GM 52.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.74%
GM growth 5Y1.61%
ALHYP.PA Yearly Profit, Operating, Gross MarginsALHYP.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ALHYP is still creating some value.
Compared to 1 year ago, ALHYP has about the same amount of shares outstanding.
Compared to 5 years ago, ALHYP has about the same amount of shares outstanding.
The debt/assets ratio for ALHYP is higher compared to a year ago.
ALHYP.PA Yearly Shares OutstandingALHYP.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
ALHYP.PA Yearly Total Debt VS Total AssetsALHYP.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.38, we must say that ALHYP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.38, ALHYP is doing worse than 72.00% of the companies in the same industry.
A Debt/Equity ratio of 0.31 indicates that ALHYP is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.31, ALHYP perfoms like the industry average, outperforming 54.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 0.38
ROIC/WACC1.02
WACC6.31%
ALHYP.PA Yearly LT Debt VS Equity VS FCFALHYP.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 1.01 indicates that ALHYP should not have too much problems paying its short term obligations.
ALHYP has a Current ratio of 1.01. This is in the lower half of the industry: ALHYP underperforms 74.00% of its industry peers.
ALHYP has a Quick Ratio of 1.01. This is a normal value and indicates that ALHYP is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ALHYP (1.01) is worse than 72.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
ALHYP.PA Yearly Current Assets VS Current LiabilitesALHYP.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

3

3. Growth

3.1 Past

The earnings per share for ALHYP have decreased strongly by -86.35% in the last year.
Looking at the last year, ALHYP shows a quite strong growth in Revenue. The Revenue has grown by 9.77% in the last year.
The Revenue has been growing by 16.33% on average over the past years. This is quite good.
EPS 1Y (TTM)-86.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.5%
Revenue 1Y (TTM)9.77%
Revenue growth 3Y11.26%
Revenue growth 5Y16.33%
Sales Q2Q%3.69%

3.2 Future

ALHYP is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.53% yearly.
The Revenue is expected to grow by 6.73% on average over the next years.
EPS Next Y-48.06%
EPS Next 2Y-20.76%
EPS Next 3Y-7.53%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y6.84%
Revenue Next 3Y6.73%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALHYP.PA Yearly Revenue VS EstimatesALHYP.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
ALHYP.PA Yearly EPS VS EstimatesALHYP.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1 -1.5

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 40.91, which means the current valuation is very expensive for ALHYP.
The rest of the industry has a similar Price/Earnings ratio as ALHYP.
ALHYP's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.11.
A Price/Forward Earnings ratio of 10.79 indicates a reasonable valuation of ALHYP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALHYP indicates a somewhat cheap valuation: ALHYP is cheaper than 70.00% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.55. ALHYP is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 40.91
Fwd PE 10.79
ALHYP.PA Price Earnings VS Forward Price EarningsALHYP.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALHYP is valued a bit cheaper than the industry average as 72.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.56
ALHYP.PA Per share dataALHYP.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

A cheap valuation may be justified as ALHYP's earnings are expected to decrease with -7.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.76%
EPS Next 3Y-7.53%

0

5. Dividend

5.1 Amount

No dividends for ALHYP!.
Industry RankSector Rank
Dividend Yield N/A

HIPAY GROUP SA

EPA:ALHYP (10/31/2025, 7:00:00 PM)

9

-0.4 (-4.26%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryFinancial Services
Earnings (Last)09-17 2025-09-17
Earnings (Next)11-04 2025-11-04
Inst Owners0.45%
Inst Owner ChangeN/A
Ins Owners50.11%
Ins Owner ChangeN/A
Market Cap56.79M
Revenue(TTM)75.63M
Net Income(TTM)1.16M
Analysts84.44
Price Target17.34 (92.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-36.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.25%
Valuation
Industry RankSector Rank
PE 40.91
Fwd PE 10.79
P/S 0.75
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB N/A
EV/EBITDA 7.56
EPS(TTM)0.22
EY2.44%
EPS(NY)0.83
Fwd EY9.27%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS11.98
BVpS5.96
TBVpS-1.48
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.43
Profitability
Industry RankSector Rank
ROA 0.55%
ROE 3.09%
ROCE 8.75%
ROIC 6.43%
ROICexc 8.22%
ROICexgc N/A
OM 6.24%
PM (TTM) 1.54%
GM 52.12%
FCFM N/A
ROA(3y)-0.13%
ROA(5y)-0.88%
ROE(3y)-2.18%
ROE(5y)-5.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.74%
GM growth 5Y1.61%
F-ScoreN/A
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA 1.25
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z 0.38
F-ScoreN/A
WACC6.31%
ROIC/WACC1.02
Cap/Depr(3y)82.18%
Cap/Depr(5y)97.59%
Cap/Sales(3y)5.73%
Cap/Sales(5y)6.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.5%
EPS Next Y-48.06%
EPS Next 2Y-20.76%
EPS Next 3Y-7.53%
EPS Next 5YN/A
Revenue 1Y (TTM)9.77%
Revenue growth 3Y11.26%
Revenue growth 5Y16.33%
Sales Q2Q%3.69%
Revenue Next Year7.14%
Revenue Next 2Y6.84%
Revenue Next 3Y6.73%
Revenue Next 5YN/A
EBIT growth 1Y-25.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.5%
EBIT Next 3Y15.1%
EBIT Next 5YN/A
FCF growth 1Y66.33%
FCF growth 3Y33.78%
FCF growth 5YN/A
OCF growth 1Y34.3%
OCF growth 3Y5.28%
OCF growth 5Y82.77%

HIPAY GROUP SA / ALHYP.PA FAQ

What is the ChartMill fundamental rating of HIPAY GROUP SA (ALHYP.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALHYP.PA.


Can you provide the valuation status for HIPAY GROUP SA?

ChartMill assigns a valuation rating of 3 / 10 to HIPAY GROUP SA (ALHYP.PA). This can be considered as Overvalued.


What is the profitability of ALHYP stock?

HIPAY GROUP SA (ALHYP.PA) has a profitability rating of 3 / 10.


How financially healthy is HIPAY GROUP SA?

The financial health rating of HIPAY GROUP SA (ALHYP.PA) is 2 / 10.


Can you provide the expected EPS growth for ALHYP stock?

The Earnings per Share (EPS) of HIPAY GROUP SA (ALHYP.PA) is expected to decline by -48.06% in the next year.